Seki Syrup 200 ml bottle 3.54 mg / ml

WARNINGS
The syrup contains 450 mg of sucrose per ml. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. In the case of diabetic subjects who follow low-calorie diets, it must be borne in mind that the preparation contains sugar. The syrup also contains parahydroxybenzoates (E218 and E216) which can cause allergic reactions, including delayed type.
PHARMACOTHERAPEUTIC CATEGORY
Cough suppressants, excluding associations with expectorants.
STORAGE
Store at a temperature not exceeding 30 degrees C.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity to the active substance and to any of the excipients.
NAME
SEKI 3.54 MG / ML SYRUP
EXCIPIENTS
3.54 mg / ml syrup: microcrystalline cellulose, carmellose sodium, polyoxyl-40-stearate, sucrose, methyl-para-hydroxybenzoate, propyl-para-hydroxybenzoate, banana essence, purified water.
SIDE EFFECTS
Frequencies of adverse reactions: very common (> = 1/10); common (> = 1/100, <1/10); uncommon (> = 1/1000, <1/100); rare (> = 1/10000, <1/1000); very rare (<1/10000), not known. Disorders of the immune system. Not known: anaphylactic / anaphylactoid reaction. Nervous system disorders. Uncommon: drowsiness, dry mouth. Skin and subcutaneous tissue disorders. Not known: urticaria. Pediatrics: Clinical studies and post-marketing surveillance with cloperastine did not reveal relevant differences in the nature, frequency, severity and reversibility of adverse reactions between the adult and pediatric population. Report any suspected adverse reactions via the national reporting system.
PREGNANCY AND BREASTFEEDING
No information is available regarding the use of the drug in pregnancy. Although the toxicity studies carried out during pregnancy in animals did not show teratogenic activity and fetotoxicity, it is a good prudent rule not to take the drug in the first months of pregnancy and in the further period only in case of actual need. under the direct supervision of the doctor. The drug and / or its metabolites are not known to be excreted in human milk; as a risk to the suckling child cannot be excluded, it should not be used during breastfeeding.
INDICATIONS
Cough suppressant.
INTERACTIONS
No interaction studies have been conducted in humans. It is not recommended, both in adult patients and in children, the concomitant use of the drug with alcohol, antihistamines, anticholinergics, sedatives. It is not known whether in pediatric age the extent of the interactions reported above is similar to that in adulthood. There is no information regarding any drug interactions with laboratory tests. No information is available regarding the interaction of cloperastine with food, therefore it is not recommended to be taken with meals.
DOSAGE
Daily dose. Adults: 2 small glasses ("Adult" mark of the dispenser included in the package; one "Adult" mark corresponds to 7.5 ml of syrup) in the evening at bedtime; a small glass in the morning, a small glass in the afternoon. Children. After two years: two small glasses ("Children" mark of the dispenser included in the package; one "Children" mark corresponds to 3.75 ml of syrup) in the evening before night rest; a small glass in the morning, a small glass in the afternoon.
ACTIVE PRINCIPLES
3.54 mg / ml syrup: 100 ml contain 354 mg cloperastine fendizoate equal to 180 mg cloperastine.